Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Phenactropinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.69 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.69 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenactropinium SCHEMBL8916468 | 0.99 | CHRM2 (0.70) | CHRM2CHRM1CHRNA7CHRM3LMNA | |
| Phenactropinium SCHEMBL29387827 | 0.99 | CHRM2 (0.70) | CHRM2CHRM1CHRNA7CHRM3LMNA | |
| Methylhomatropine SCHEMBL17179980 | 0.82 | CHRM2 (1.00) | CHRM2CHRM1CHRM3LMNACYP2D6 | |
| Methylhomatropine SCHEMBL16784195 | 0.82 | CHRM2 (1.00) | CHRM2CHRM1CHRM3LMNACYP2D6 | |
| Methylhomatropine SCHEMBL30516140 | 0.82 | CHRM2 (1.00) | CHRM2CHRM1CHRM3LMNACYP2D6 | |
| Methylhomatropine SCHEMBL77827 | 0.81 | CHRM2 (0.97) | CHRM2CHRM1CHRM3LMNACYP2D6 | |
| Methylhomatropine SCHEMBL29555824 | 0.81 | CHRM2 (0.97) | CHRM2CHRM1CHRM3LMNACYP2D6 | |
| Methylhomatropine SCHEMBL20659943 | 0.81 | CHRM2 (0.97) | CHRM2CHRM1CHRM3LMNACYP2D6 | |
| Methylhomatropine SCHEMBL613580 | 0.81 | CHRM2 (0.97) | CHRM2CHRM1CHRM3LMNACYP2D6 | |
| Fentonium SCHEMBL251444 | 0.80 | CHRM2 (0.68) | CHRM2CHRM1CHRM3LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4581143-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | University of Rochester (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250066790-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODIFYING PROTEIN EXPRESSION | UNIVERSITY OF ROCHESTER | 2025-02-27 | — | — | US | disclosed |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2025-02-06 | — | — | US | disclosed |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF ROCHESTER | 2025-01-16 | — | — | US | disclosed |
| US-20250018009-A1 | SERUM RESPONSE FACTOR REGENERATES SENESCENT CELLS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-01-16 | — | — | US | disclosed |
| US-20050074448-A1 | Increasing nitric oxide production; nitric oxide synthase havingTAT protein transduction domain; vascular diseases | THE CURATOR SOF THE UNIVERSITY OF MISSOURI | 2005-04-07 | — | — | US | disclosed |
| US-6846670-B2 | Genetically engineered herpes virus for the treatment of cardiovascular disease | THE UNIVERSITY OF CHICAGO (US) | 2005-01-25 | — | — | US | disclosed |
| WO-2004112763-A2 | INHIBITION OF PROTEIN KINASE C-MU (PKD) AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1434876-A1 | EXPRESSION PROFILING IN THE INTACT HUMAN HEART | The REGENTS OF THE UNIVERSITY OF COLORADO, A Body Corporate (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1356071-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | The University of Chicago (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030096782-A1 | Expression profiling in the intact human heart | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2003-05-22 | — | — | US | disclosed |
| WO-2003023066-A1 | EXPRESSION PROFILING IN THE INTACT HUMAN HEART | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20020155432-A1 | Genetically engineered herpes virus for the treatment of cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-24 | — | — | US | disclosed |
| WO-2002045431-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF CHICAGO (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | CHRM2 3684/4885CHRM1 3938/4885CHRM3 4187/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | CHRM2 971/4885CHRM1 732/4885CHRM3 967/4885 |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UPF1, TNNI3, TNNT2 | CHRM2 4418/4885CHRM1 4199/4885CHRM3 4176/4885 |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | CHRM2 4663/4885CHRM1 4416/4885CHRM3 3495/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | CHRM2 89/4885CHRM1 76/4885CHRM3 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.